logo
Plus   Neg
Share
Email

Rolls-Royce Names Panos Kakoullis CFO And Executive Director, Effective May 3

Rolls-Royce Holdings plc. (RYCEF.PK,RR.L,RYCEY.PK) announced Monday the appointment of Panos Kakoullis as Chief Financial Officer and Executive Director, succeeding Stephen Daintith who is leaving the company as announced last year.

Daintith will leave Rolls-Royce on March 19, shortly after the publication of the Group's full year 2020 results, while Kakoullis will take up his new role on May 3.

To support the company in the period of transition, Ben Fidler, who is currently acting as Deputy CFO and joined the Executive Team effective January 1, will be appointed as Interim CFO.

Fidler, who joined Rolls-Royce in 2017 from Deutsche Bank, will continue to carry out his current responsibilities as Vice President of Business Performance in addition to his new role.

The new CFO Kakoullis more recently joined PA Consulting. He started his career at Deloitte, and was, until May 2019, Global Head of Deloitte's Audit and Assurance Practice.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
United Airlines is adding three new flights to Croatia, Greece and Iceland, which are starting to reopen to vaccinated visitors. The move would give travelers more options for summer travel by flying direct to these countries. Last month's searches on United.com for flights to Croatia, Greece and Iceland were up 61 percent. Johnson & Johnson's (JNJ) Covid-19 vaccine is expected to be back on track as early as this weekend as a decision is expected after the advisory panel meeting of the U.S. Centers for Disease Control and Prevention (CDC) slated on April 23, according to Dr. Anthony Fauci, the chief medical adviser to President Joe Biden. MK-4482, the experimental antiviral drug for COVID-19, showed promise to prevent and treat SARS-CoV-2 infection in hamster study, according to the scientists of National Institutes of Health or NIH. The drug significantly decreased levels of virus and disease damage in the lungs of hamsters treated for SARS-CoV-2 infection. MK-4482, delivered orally, is now in Phase 2 and 3 human clinical studies.
Follow RTT